NCT02953340 SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide Status COMPLETED Phase PHASE3
NCT02953184 Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy Status UNKNOWN Phase PHASE2
NCT02951819 A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02951728 Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma Status UNKNOWN Phase PHASE1/PHASE2
NCT02950051 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation Status COMPLETED Phase PHASE3
NCT02948101 PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Status WITHDRAWN Phase PHASE2
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients Status COMPLETED Phase PHASE1/PHASE2
NCT02937844 Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme Status UNKNOWN Phase PHASE1
NCT02937662 Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML Status COMPLETED Phase PHASE2
NCT02926833 Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Status COMPLETED Phase PHASE1/PHASE2
NCT02924753 The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). Status UNKNOWN Phase PHASE1
NCT02918747 PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage Status UNKNOWN Phase PHASE2
NCT02918292 Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) Status COMPLETED Phase PHASE2
NCT02911142 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02889523 Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2